Missense variant in the skeletal muscle glycogen-targeting subunit of protein phosphatase 1 (PP1); reduces effective PP1 activity at the glycogen particle, impairing insulin-stimulated glycogen synthesis and increasing type 2 diabetes risk

Phase II detoxification enzyme that reduces quinones and recycles CoQ10 to its active ubiquinol form; variant causes near-complete loss of enzyme activity

Intronic CYP1A2 variant near the 5' end; G allele is associated with altered metabolic ratios for CYP1A2 substrates including escitalopram

Estrogen receptor alpha intron variant affecting receptor expression and estrogen sensitivity

3' UTR variant in the PGC-1alpha gene that may alter PPARGC1A mRNA stability or miRNA regulation, with potential downstream effects on mitochondrial biogenesis and fat oxidation capacity

Intronic regulatory variant in FADS2 (Block 2 haplotype) that reduces basal FADS1 and FADS2 expression through a conserved intron 1 regulatory locus, impairing delta-6 desaturase activity and lowering circulating arachidonic acid, EPA, and DHA; captures an independent regulatory signal from the rs174568/rs174575 haplotype block

Intronic FOXO3 variant that disrupts an NKX3 transcription factor binding site; the longevity-associated C allele confers protection in male centenarians independent of rs2802292

The most common pathogenic mutation in FKRP causing limb-girdle muscular dystrophy R9 (LGMD R9) in European populations; homozygous carriers develop progressive proximal muscle weakness

Promoter variant that elevates baseline C-reactive protein levels, increasing cardiovascular inflammation risk and stroke susceptibility

Pathogenic ACADVL frameshift deletion causing premature protein truncation; heterozygous carriers are healthy but carry reproductive risk, while biallelic disruption causes VLCAD deficiency requiring lifelong dietary management